Faecal microbiota transplantation: From practice to legislation before considering industrialization

Clinical Microbiology and Infection

Volumn 20, Issue 11, 2014, Pages 1112-1118

  Lagier, J C ^a,b  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b HÔPITAL NORD   (France)

Author keywords

Clostridium difficile; Faecal microbiota transplant; Industrialization; Pills; Regulation

Indexed keywords

ADMINISTRATION OF DRUGS, FOOD AND CHEMICALS; ADVERSE OUTCOME; ALTERNATIVE MEDICINE; CLOSTRIDIUM DIFFICILE INFECTION; DONOR SELECTION; ETHICS; EVIDENCE BASED PRACTICE; FECAL BANK; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; FECES MICROFLORA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE FACILITY; HUMAN; INDUSTRIALIZATION; MEDICOLEGAL ASPECT; NONHUMAN; PATIENT SAFETY; PATIENT SELECTION; PILL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRAM ACCEPTABILITY; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYNTHETIC BIOLOGY; THERAPY EFFECT; TREATMENT INDICATION; ADVERSE EFFECTS; BIOLOGICAL THERAPY; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; FECES; FRANCE; INDUSTRY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RECURRENT DISEASE; UNITED STATES;

CLOSTRIDIUM DIFFICILE;

BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DIARRHEA; DONOR SELECTION; FECES; FRANCE; HUMANS; INDUSTRY; RECURRENCE; UNITED STATES;

EID: 84916937261     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12795     Document Type: Review

References (44)

1. Freeman J, Bauer MP, Baines SD et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23: 529-549.
2. He M, Miyajima F, Roberts P et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013; 45: 109-113.
3. Birgand G, Blanckaert K, Carbonne A et al. Investigation of a large outbreak of Clostridium difficile PCR-ribotype 027 infections in northern France, 2006-2007 and associated clusters in 2008-2009. Euro Surveill 2010; 15: pii: 19597.
4. Mascart G, Delmee M, Van Broeck J et al. Impact of ribotype 027 on Clostridium difficile infection in a geriatric department. Eur J Clin Microbiol Infect Dis 2013; 32: 1177-1182.
5. Johnson S. Editorial commentary: changing epidemiology of Clostridium difficile and emergence of new virulent strains. Clin Infect Dis 2014; 58: 1731-1733.
6. Lagier JC, Dubourg G, Cassir N et al. Clostridium difficile 027 emerging outbreak in Marseille, France. Infect Control Hosp Epidemiol 2013; 34: 1339-1341.
7. Zipursky JS, Sidorsky TI, Freedman CA et al. Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. Clin Infect Dis 2012; 55: 1652-1658.
8. Eiseman B, Silen W, Bascom GS et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44: 854-859.
9. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002.
10. Van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
11. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20(suppl 2): 1-26.
12. Konijeti GG, Sauk J, Shrime MG et al. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014; 58: 1507-1514.
13. Kelly CR, Ihunnah C, Fischer M et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109: 1065-1071.
14. Rubin DT. Curbing our enthusiasm for fecal transplantation in ulcerative colitis. Am J Gastroenterol 2013; 108: 1631-1633.
15. Smits LP, Bouter KE, de Vos WM et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946-953.
16. Angelberger S, Reinisch W, Makristathis A et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 2013; 108: 1620-1630.
17. Smith MB, Kelly C, Alm EJ. Policy: how to regulate faecal transplants. Nature 2014; 506: 290-291.
18. Food and Drug Administration USA. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection non responsive to standard therapy. 2013. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM361393.pdf (last accessed 1 September 2014).
19. Fox JL. Fecal transplants to follow FDA rules. Nat Biotechnol 2013; 31: 583.
20. Agence nationale de sécurité du médicament et des produits de santé. La transplantation de microbiote fécal et son encadrement dans les essais cliniques. 2014. Available at: http://ansm.sante.fr/var/ansm_site/storage/original/application/5e5e01018303790194275ded0e02353c.pdf (last accessed 1 September 2014).
21. National Institute for Health and Care Excellence. Faecal microbiota transplant for reccurent Clostridium difficile infection. 2014. Available at: http://www.nice.org.uk/guidance/ipg485 (last accessed 1 September 2014).
22. Lagier JC, Million M, Hugon P et al. Human gut microbiota: repertoire and variations. Front Cell Infect Microbiol 2012; 2: 136.
23. Schunemann M, Oette M. Fecal microbiota transplantation for Clostridium difficile-associated colitis in a severely immunocompromised critically ill AIDS patient: a case report. AIDS 2014; 28: 798-799.
24. Woerther PL, Burdet C, Chachaty E et al. Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev 2013; 26: 744-758.
25. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48: 693-702.
26. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36 : 503-516.
27. Brandt LJ, Aroniadis OC, Mellow M et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 1079-1087.
28. Youngster I, Sauk J, Pindar C et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58: 1515-1522.
29. Hamilton MJ, Weingarden AR, Sadowsky MJ et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 761-767.
30. Ratner M. Fecal transplantation poses dilemma for FDA. Nat Biotechnol 2014; 32: 401-402.
31. Moore T, Rodriguez A, Bakken JS. Fecal microbiota transplantation: a practical update for the infectious disease specialist. Clin Infect Dis 2014; 58: 541-545.
32. Faith JJ, Guruge JL, Charbonneau M et al. The long-term stability of the human gut microbiota. Science 2013; 341: 1237439.
33. Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-484.
34. Million M, Lagier JC, Yahav D et al. Gut bacterial microbiota and obesity. Clin Microbiol Infect 2013; 19: 305-313.
35. de Vos WM. Fame and future of faecal transplantations-developing next-generation therapies with synthetic microbiomes. Microb Biotechnol 2013; 6: 316-325.
36. Jorup-Ronstrom C, Hakanson A, Sandell S et al. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 2012; 47: 548-552.
37. Petrof EO, Gloor GB, Vanner SJ et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013; 1: 3.
38. Hugon P, Lagier JC, Robert C et al. Molecular studies neglect apparently gram-negative populations in the human gut microbiota. J Clin Microbiol 2013; 51: 3286-3293.
39. Lagier JC, Armougom F, Million M et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect 2012; 18: 1185-1193.
40. Seekatz AM, Aas J, Gessert CE et al. Recovery of the gut microbiome following fecal microbiota transplantation. MBio 2014; 5: e00893-14.
41. IDWeek Website. Fecal transplant pill knocks out recurrent C. diff infection, study shows. 2014. Available at: http://www.idweek.org/pr-2013-cdiff/ (last accessed 1 September 2014).
42. NCT01914731. Fecal microbiota transplant for relapsing Clostridium difficile infection in adults and children using a frozen encapsulated inoculum. 2014. Available at: http://clinicaltrials.gov/show/NCT01914731 (last accessed 1 September 2014).
43. Dinleyici EC, Eren M, Ozen M et al. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther 2012; 12: 395-410.
44. Singh R, Van Nood E, Nieuwdorp M et al. Donor faeces infusion for eradication of extended-spectrum β-lactamase-producing Escherichia coli in a patient with end-stage renal disease. Clin Microbiol Infect 2014; doi: 10.1111/1469-0691.12683.